References
Fonner VA, Dalglish SL, Kennedy CE, et Effectiveness and safety of oral HIV preexposure prophylaxis forall populations. AIDS 2016; 30:1973-83. Haberer Current concepts for PrEP adherence in the PrEP revolution: from clinical trials to routinepractice. Curr Opin HIV AIDS 2016;11:10-7. Van Damme L, Corneli A, Ahmed K, et Preexposure prophylaxis for HIV infection among African […]
Behavioral strategies to reduce risk
In the era of human immunodeficiency virus (HIV) pre-exposure prophylaxis (PrEP) and treatment as prevention, behavioural methods of risk reduction – including condom use, clean injecting equipment, HIV serosorting, strategic positioning, and negotiated safe practices with sexual partners– retain their importance in preventing HIV transmission (Box 11.1). However, some vulnerable individuals, particularly some cis-gender and […]
Improving medication adherence
Medication adherence is critical to achieving the maximum prevention benefit of pre-exposure prophylaxis (PrEP) and reducing the risk of selecting for a drug-resistant virus in the event of human immunodeficiency virus (HIV) acquisition 1, 2. In randomised, blinded, placebo-controlled trials of PrEP, adherence varied 1 and was lower among cis-gender women in some studies 3, […]